Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

医学 荟萃分析 胰高血糖素样肽1受体 内科学 2型糖尿病 糖尿病 梅德林 重症监护医学 生物信息学 药理学 兴奋剂 受体 内分泌学 生物 政治学 法学
作者
Naveed Sattar,Matthew M.Y. Lee,Søren Lund Kristensen,Kelley R. Branch,Stefano Del Prato,Nardev S. Khurmi,Carolyn S.P. Lam,Renato D. Lópes,John J.V. McMurray,Richard E. Pratley,Julio Rosenstock,Hertzel C. Gerstein
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:9 (10): 653-662 被引量:1490
标识
DOI:10.1016/s2213-8587(21)00203-5
摘要

Summary

Background

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes.

Methods

We did a meta-analysis, including new data from AMPLITUDE-O, using a random effects model to estimate overall hazard ratio (HR) for MACE; its components; all-cause mortality; hospital admission for heart failure; a composite kidney outcome consisting of development of macroalbuminuria, doubling of serum creatinine, or at least 40% decline in estimated glomerular filtration rate (eGFR), kidney replacement therapy, or death due to kidney disease; worsening of kidney function, based on eGFR change; and odds ratios for key safety outcomes (severe hypoglycaemia, retinopathy, pancreatitis, and pancreatic cancer). We also examined MACE outcome in patient subgroups on the basis of MACE incidence rates in the placebo group, presence or absence of cardiovascular disease, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age, and eGFR. We searched PubMed for eligible trials reporting MACE (ie, cardiovascular death, myocardial infarction, or stroke), up to June 9, 2021. We meta-analysed data from published randomised placebo-controlled trials testing either injectable or oral GLP-1 receptor agonists in patients with type 2 diabetes. We restricted the search to trials of more than 500 patients with a primary outcome that included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This meta-analysis was registered on PROSPERO, CRD42021259711.

Findings

Of 98 articles screened, eight trials comprising 60 080 patients fulfilled the prespecified criteria and were included. Overall, GLP-1 receptor agonists reduced MACE by 14% (HR 0·86 [95% CI 0·80–0·93]; p<0·0001), with no significant heterogeneity across GLP-1 receptor agonist structural homology or eight other examined subgroups (all pinteraction≥0·14). GLP-1 receptor agonists reduced all-cause mortality by 12% (HR 0·88 [95% CI 0·82–0·94]; p=0·0001), hospital admission for heart failure by 11% (HR 0·89 [95% CI 0·82–0·98]; p=0·013), and the composite kidney outcome by 21% (HR 0·79 [95% CI 0·73–0·87]; p<0·0001), with no increase in risk of severe hypoglycaemia, retinopathy, or pancreatic adverse effects. In sensitivity analyses removing the only trial restricted to patients with an acute coronary syndrome (ELIXA), all benefits marginally increased, including the outcome of worsening of kidney function, based on eGFR change (HR 0·82 [95% CI 0·69–0·98]; p=0·030).

Interpretation

GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MACE components, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.

Funding

None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
词词完成签到,获得积分10
1秒前
诗谙发布了新的文献求助30
1秒前
gala的夏天发布了新的文献求助10
1秒前
我是老大的应助被欣喜若灵采纳,获得10
1秒前
2秒前
molihuakai的应助被王梦姣采纳,获得20
2秒前
贾瑞瑞完成签到 ,获得积分10
2秒前
爱吃肉肉的蚂蚁完成签到,获得积分20
2秒前
2秒前
伊莎贝儿完成签到,获得积分10
2秒前
YHQ完成签到,获得积分10
3秒前
3秒前
JamesPei的应助被sskk采纳,获得10
4秒前
4秒前
Jing发布了新的文献求助10
5秒前
汪汪智完成签到,获得积分10
5秒前
小匹夫完成签到,获得积分10
5秒前
我是老大的应助被赵琪采纳,获得10
5秒前
科研通AI65的应助被珍珠采纳,获得10
5秒前
酷酷的冰淇淋完成签到 ,获得积分10
5秒前
pgr发布了新的文献求助10
6秒前
JIAJIAJIA发布了新的文献求助10
6秒前
whb发布了新的文献求助10
6秒前
小猪熊发布了新的文献求助10
6秒前
蛋蛋发布了新的文献求助10
7秒前
7秒前
忧心的翎发布了新的文献求助10
7秒前
上好佳完成签到,获得积分10
7秒前
打打的应助被野七采纳,获得10
8秒前
完美世界的应助被CJY采纳,获得10
8秒前
8秒前
8秒前
9秒前
贵金属LiLi发布了新的文献求助10
9秒前
乐乐的应助被SUYIFEI采纳,获得10
9秒前
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460